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a  b  s  t  r  a  c  t
Ten  monoclonal  antibodies  (MAbs)  against  rabies  virus,  including  IgG3,  IgG2a,  IgM,  and  an  IgG2b
isotype,  were  produced  and  characterized  using  neutralization,  ELISA,  immunodot-blot,  and  immunoﬂu-
orescence  assays.  MAb  8D11,  which  recognized  rabies  virus  glycoprotein,  was  found  to  neutralize  rabies
virus  in  vitro.  When  submitted  to  an  immunoﬂuorescence  assay,  seven  MAbs  showed  different  reactivity
against  35  Brazilian  rabies  virus  isolates.  Three  MAbs  (LIA  02, 3E6,  and  9C7)  only  failed  to  recognize  oneeywords:
abies
onoclonal antibody
razilian  wild rabies isolates
ixed  rabies virus strains
or  two  virus  isolates,  whereas  MAb  6H8  was  found  to be reactive  against  all  virus  isolates  tested.  MAbs
were  also  evaluated  for their  immunoreactivity  against  ﬁxed  rabies  virus  strains  present  in  human  and
veterinary  commercial  vaccines.  MAbs  LIA  02,  6H8,  and  9C7  reacted  against  all vaccine  strains,  while  the
remaining  MAbs  recognized  at  least  76%  of  vaccine  strains  tested.  This  research  provides  a set of  MAbs
with  potential  application  for  improving  existing  or developing  new  diagnostic  tests  and  immunoassays.. Introduction
Despite being known for more than three millennia, rabies, a
atal encephalomyelitis, still infects many humans, as well as, many
omestic and wild animals around the world. The disease is caused
y the rabies virus, a single-stranded RNA virus belonging to the
habdoviridae family, genus Lyssavirus (Warrel and Warrel, 2004).
The virion is composed of two structural units, the ribonucle-
protein (RNP) and an envelope. RNP is formed by RNA and three
iral proteins, namely the nucleoprotein, the phosphoprotein, and
he RNA-dependent RNA polymerase. The envelope consists of gly-
oproteins anchored to a host-derived lipid bilayer surrounding the
atrix protein. The glycoprotein allows virus attachment to cellu-
ar receptors, mediates membrane fusion, and serves as a target for
irus-neutralizing antibodies (Rupprecht et al., 2002; Schnell et al.,
010).
The ﬁrst monoclonal antibodies (MAbs) against the rabies virus
ere produced by Wiktor and Koprowski (1978) and initially were
mployed for the detection of antigenic variants among several
trains of rabies virus. Anti-RNP and anti-glycoprotein rabies MAbs
ave been used to characterize some strains of rabies virus and
o distinguish rabies from other rabies-related viruses (Flamand
t al., 1980a,b). MAbs also proved to be important tools for diagno-
is and immunoassays (Lembo et al., 2006; Zhang et al., 2009), and
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the protective activity of MAbs are being investigated currently as a
possible post-exposure treatment (Bakker et al., 2008; Müller et al.,
2009).
Antigenic analysis of rabies isolates in Latin America is carried
out mainly by using a panel of eight MAbs established by Diaz
et al. (1994) and provided by the Centers for Disease Control and
Prevention (Atlanta, USA). This panel of MAbs helps to identify a
characteristic antigenic make up in rabies viruses circulating in sta-
ble enzootics within a speciﬁc species of carnivore or bat. Thus, by
identifying the rabies virus antigenic pattern, the most likely rabies
transmitter or rabies reservoir can be inferred. However, as a con-
sequence of improved rabies surveillance programs and the natural
evolution of rabies viruses in Brazil and several other countries of
the Americas, new antigenic variants have been identiﬁed and pos-
sibly are associated with different species of carnivores and bats.
These new antigenic variants have resulted in the restricted use
of the current MAb  panel to identify potentially emergent rabies
reservoirs. Thus, although a large number of anti-rabies MAbs were
reported in the last few years, a demand exists for the production
of new MAbs capable of detecting variants which are incompatible
to the panel used in Brazil.
In  addition, rabies conjugates for diagnostic use in Brazil are
obtained mainly from the serum samples of immunized ani-
mals. The use of MAbs could increase the speciﬁcity of rabies
Open access under the Elsevier OA license.conjugates (Woldehiwet, 2005). The production of MAbs also
attracts investment in simple and fast diagnostic tests to evaluate
infection in ﬁeld conditions. Finally, the test most widely employed
to determine the strength of the rabies vaccine is the NIH test,
rologic
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hich presents several problems in terms of reproducibility. The
esults from this test do not have a satisfactory correlation with
he formation of virus-neutralizing antibodies (Barth et al., 1988).
ince the rabies glycoprotein induces neutralizing antibodies and
rotection, the standardization of an immunoassay using anti-
lycoprotein MAbs could be researched as a possible replacement
or the NIH test in determining rabies vaccine strength. Consider-
ng these possible uses for rabies MAbs, the present study reports
he production of ten MAbs, including a virus-neutralizing MAb,
hat react against wild rabies isolates and ﬁxed rabies strains. The
erspective of further applications for these MAbs will be dis-
ussed.
. Animals and methods
.1. Animals
Male Balb/c mice (30- to 45-days-old, mean weight of 20 g) were
sed in the immunization protocols. Animals were maintained at
he Animal Facility of the Microbiology, Immunology, and Parasitol-
gy Department at the Federal University of Santa Catarina. Animal
rocedures were approved by the Federal University of Santa Cata-
ina Ethics Committee on Animal Research.
.2. Cell lines
Mouse myeloma cell line P3X63Ag8.653 (ATCC CRL-1580) and
ybridomas were maintained in RPMI-1640 medium (Cultilab,
ampinas, Brazil) and supplemented with 20% fetal bovine serum
FBS – Cultilab), 23.8 mM  sodium bicarbonate, 0.2 mM l-glutamine,
.0 mM sodium pyruvate, 9.6 mM HEPES, and antibiotics (100 IU/ml
enicillin, 100 g/ml streptomycin, and 0.25 g/ml amphotericin
 – Sigma–Aldrich, St. Louis, USA) at 37 ◦C, 5% CO2 atmosphere.
aby hamster kidney cells (BHK-21, ATCC CCL-10) and N2A
ells (ATCC CCL-131) were cultured in Dulbecco’s Modiﬁed Eagle
edium/Nutrient Ham F12 (DMEM F12 – Cultilab) with 10% FBS for
HK-21 and 20% FBS for N2A cells, 14.0 mM sodium bicarbonate and
ntibiotics at 37 ◦C, 5% CO2 atmosphere. S2MtRVGP-Hy cells (Lemos
t al., 2009) were cultured in SF-900 II SFM medium (Invitrogen,
rand Island, USA) and maintained at 28 ◦C.
.3. Animal immunization
Five immunization protocols were carried out. In the ﬁrst proto-
ol, three Balb/c mice were immunized four times intraperitoneally
i.p.) with 500 l of human rabies vaccine (VeroRabTM – Aventis
asteur, Lyon, France) diluted 1:10 in PBS on days 0, 7, 14, and 28.
In the second protocol, two mice were immunized with wild
abies virus isolated from a bovine infected naturally by a vampire
at in Passos de Torres, in the state of Santa Catarina, Brazil. Mice
ere immunized subcutaneously (s.c.) with 500 l of UV light-
nactivated 10% infected mouse brain suspension (∼320 cell culture
nfectious dose 50% – CCID50%), mixed with complete Freund’s adju-
ant (Sigma–Aldrich). Seven days later, a second subcutaneous
mmunization was performed using the same amount of anti-
en mixed with incomplete Freund’s adjuvant (Sigma–Aldrich).
wo additional doses were given i.p. at 7-day intervals using
he same antigen dose, followed by a ﬁfth i.p. dose one month
ater.
In two other protocols, mice were immunized with wild rabies
iruses isolated from Nyctinomops laticaudatus (Nl) and Eptesicus
urinalis (Ef) bats. Four Balb/c mice received four 500 l doses of
V light-inactivated 20% infected mouse brain suspensions diluted
:5 in PBS, two mice received the Nl virus (∼20 CCID50%), and the
emaining two mice received the Ef virus (∼80 CCID50%). Doses were
dministered s.c on day 0 with complete Freund’s adjuvant, and i.p.al Methods 175 (2011) 66– 73 67
on days 7, 14, and 36 without adjuvant. Nineteen days later, mice
were challenged with the respective virus isolates inoculated by
footpad injection, followed by boosting with inactivated suspen-
sion on day 72.
In the ﬁfth protocol, three mice received four doses of a recom-
binant fragment of the rabies virus glycoprotein, rGERA179–281
(Bassi et al., 2008). Doses containing 40 g of the protein were
administered s.c. on day 0 in complete Freund’s adjuvant, on day 7
in incomplete Freund’s adjuvant, and i.p. on days 14 and 28 without
any adjuvant. Mice were boosted further with live PV rabies virus
strain (∼64 CCID50%) by footpad injection on day 34.
2.4. Monoclonal antibody production
Three days after the last immunization or eight days after the
boost (protocol three), mice were humanely killed and their spleens
were collected aseptically. Cells were released by applying gen-
tle pressure to the capsule of the organ and placing it between
two  glass slides, and then the content was ﬁltered in nylon mem-
branes. Red blood cells were lysed using 5 ml  of cold lysis solution
(168.08 mM ammonium chloride, 9.98 mM  potassium bicarbon-
ate, 0.09 mM EDTA, pH 7.4). After two washes with RPMI-1640
medium, splenocytes were fused with P3X63Ag8.653 myeloma
cells using polyethylene glycol 4000 (PEG – Sigma–Aldrich) as the
fusion agent. The fusion was performed by adding PEG 50% in RPMI-
1640 medium without FBS for 2 min, followed by washing with
RPMI-1640 medium for 5 min, as described previously (Yokoyama
et al., 2006).
Hybrid cells were selected by growth in RPMI-1640 with
the supplements described above plus 0.1 mM hypoxanthine,
0.0004 mM aminopterine, and 0.016 mM  thymidine (HAT medium)
from 24 h after fusion until the 14th day. The hybridoma super-
natants were screened by indirect immunoﬂuorescence (IIF) as
described below. Hybridomas whose supernatants showed posi-
tive results by the screening tests were subjected to two rounds
of the limiting dilution method and stored in liquid nitrogen. The
immunoglobulin isotypes of the MAbs were determined using an
SBA ClonotypingTM System/HRP (Southern Biotech, Birmingham,
USA), following manufacturer instructions.
2.5. Screening test
Hybridomas secreting antibodies against rabies virus were
selected by IIF in rabies virus PV strain-infected BHK-21 cells
and in control uninfected BHK-21 cells. Cells were ﬁxed at 24 h
post-infection with 4% paraformaldehyde and permeabilized with
0.25% Triton X-100, both steps for 20 min  at room temperature.
Hybridoma supernatants were added as ﬁrst antibodies and incu-
bated for 30 min  at 37 ◦C. To detect reactive monoclonal antibodies,
incubation was  performed for 1 h at 37 ◦C with FITC-conjugated
anti-mouse immunoglobulins (Sigma–Aldrich). An Olympus IX51
microscope connected to a digital camera (Olympus DP72, Cen-
ter Valley, USA) was used to record the results. Sera from rabies
virus-immunized mice and non-correlated MAbs that bind IMNV,
a virus that infects marine invertebrates, were used as positive and
negative controls, respectively.
In addition, when mice were immunized with wild rabies virus,
hybridomas were screened by IIF on BHK-21cells infected with the
homologous virus. rGERA179–281 is a fragment of the glycoprotein
from rabies virus ERA strain and shows 98% of similarity to rabies
virus PV strain (Bassi et al., 2008). Hence, for practical issues, in
the ﬁfth immunization protocol, when mice were immunized with
this recombinant protein followed by a boost with rabies PV strain,
the only screening test performed was IIF on rabies virus PV strain-
infected BHK-21 cells.
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.6. Neutralization activity of MAbs
The rabies-speciﬁc virus-neutralizing activity of MAbs was
etermined by the simpliﬁed ﬂuorescence inhibition microtest as
escribed by Favoretto et al. (1993).  Brieﬂy, serial two-fold dilutions
f hybridoma supernatants were incubated with a rabies virus PV
train suspension at a previously established amount, enough to
nfect 90–100% of cells, for 1 h at 37 ◦C. Next, the mixture was  used
o infect 5 × 104 BHK-21 cells. After 24 h incubation at 37 ◦C in a 5%
O2 atmosphere, the cells were ﬁxed with paraformaldehyde 4%
nd submitted to IIF as described above. Virus neutralization was
etermined by comparing the number of infected cells in cultures
ncubated with antibody-treated virus to the number of infected
ells in culture incubated with untreated virus.
.7. Reaction to rGERA179–281
To detect antibodies that react against rGERA179–281, MAbs
ere tested by ELISA, using a protocol adapted from Piza et al.
1999). Brieﬂy, 96-well plates (Costar-3590, Corning, New York,
SA) were coated with rGERA179–281, 200 ng/well in 0.05M
odium carbonate–bicarbonate buffer (pH 9.6) overnight at 4 ◦C.
ll further incubation steps were performed for 1 h at 37 ◦C, unless
tated otherwise. Non-speciﬁc binding was blocked with 0.5% (w/v)
elatin in Tris–NaCl buffer (50 mM Tris, 150 mM NaCl, pH 9.6) for
0 min. MAbs were loaded onto the ELISA plate and binding was
etected using anti-mouse polyvalent immunoglobulins labeled
ith peroxidase (Sigma–Aldrich). Sera from rabies-immunized
ice and cell-free hybridoma culture medium were used as pos-
tive and negative controls, respectively. Between each step of
he reaction, microplates were washed ﬁve times with phosphate
uffered saline (PBS, pH 7.2) containing 0.05% Tween 20. Reactions
ere developed with o-fenilenodiamine (OPD) in the presence of
2O2, with absorbance measured at 492 nm using a SunriseTM Basic
ystem (Tecan, Männedorf, Switzerland).
.8. Reactivity against rabies virus glycoprotein
For rabies virus glycoprotein expression, S2MtRVGP-Hy cells
ere cultured as previously described (Lemos et al., 2009). Gly-
oprotein expression was  induced by 700 M of CuSO4 for 72 h.
 ×105 cells/well were added to a 96-well plate. After adhesion,
ells were ﬁxed with 80% acetone for 30 min  at 4 ◦C. Anti-
lycoprotein MAbs were detected by incubating the cells with
upernatants from hybridomas for 30 min  at 37 ◦C, followed by
ITC-conjugated anti-mouse immunoglobulins for 1 h at 37 ◦C. As
ositive and negative controls, sera from rabies-immunized mice
nd a non-relating MAb  against IMNV were used, respectively.
.9. Reactivity of MAbs against inactivated rabies virus present in
ommercial vaccines
Human and veterinary rabies vaccines were applied to nitro-
ellulose membranes (GE-Healthcare, Little Chalfont, UK) at a
olume of 2 l/spot to perform an immunodot-blot assay. All
urther incubation steps were carried out for 1 h at room temper-
ture. Membranes were blocked with 5% non-fat milk in TBS-T
20 mM  Tris, 137 mM NaCl, pH 7.6, containing 0.1% Tween 20)
nd incubated with hybridoma supernatants, using supernatants
ontaining a non-relating MAb  against IMNV as the negative con-
rol. Bound antibodies were detected using anti-mouse polyvalent
mmunoglobulins conjugated with peroxidase (Sigma–Aldrich).
CL Western blotting detection reagents (AmershamTM, Piscat-
way, USA) were used to detect the signals.al Methods 175 (2011) 66– 73
2.10. Reactivity of MAbs to wild rabies virus isolates
Reactivity of the MAbs against Brazilian rabies virus isolates
(Table 1) was  determined using the indirect immunoﬂuorescent
technique, carried out according to Diaz et al. (1994).  Brieﬂy, slides
with the imprint of central nervous system tissues from mice
infected with wild virus isolates were prepared. Tissues were ﬁxed
overnight in acetone at −20 ◦C and overlaid with the supernatant of
hybridomas for 30 min  at 37 ◦C. Next, individual slide impressions
were rinsed carefully with PBS, followed by the addition of anti-
mouse polyvalent FITC-conjugated immunoglobulins for 30 min  at
37 ◦C. After two  washes with PBS and one wash with distilled water,
reactions were visualized using a UV light microscope. The anti-
genic variants of the isolates were determined using the panel of
MAbs provided by CDC as well.
3. Results
3.1. Production and characterization of monoclonal antibodies
against rabies virus
Five fusion protocols were carried out. In the ﬁrst four proto-
cols, mice were immunized with rabies vaccine or an inactivated
wild rabies virus. Six stable hybridomas, which produce antibodies
that bind to rabies virus on IIF, were obtained (Fig. 1A–F). For pro-
tocols in which mice were immunized with wild rabies virus, the
same results were obtained for the IIF screening of BHK-21 cells
infected with the PV strain of rabies virus as were obtained for the
homologous virus. However, only the results obtained using the
former virus were shown. Since one of the objectives of this work
was  to produce neutralizing MAbs, a new strategy for immuniza-
tion was  achieved. Accordingly, in the ﬁfth fusion protocol, mice
were immunized with rGERA179–281, followed by boost with an
infective rabies strain to maximize the speciﬁc response to the
virus. In this protocol, four hybrid cells had positive IIF results
(Fig. 1G–J), with one producing neutralizing antibodies (Table 2).
The staining patterns of MAbs on IIF were distinct, as can be
seen in Fig. 1. The positive control and all but one MAb showed
the well-circumscribed intracytoplasmic inclusions characteristic
of anti-nucleocapside MAbs, while the neutralizing MAb  (8D11)
showed diffuse staining, predominantly in the cell membrane. The
MAbs showed no cross-reaction with non-infected BHK-21 cells
(data not shown). Isotyping of these MAbs revealed four MAbs were
IgG3, three were IgG2a, two were IgM, and one was IgG2b. All ten
revealed kappa light chains as well (Table 2). Only MAb 7B7 rec-
ognized rGERA179–281 (Table 2). MAbs secreted by hybridomas
originating from the ﬁfth protocol did not recognize the recom-
binant protein with which mice were immunized. This lack of
protein recognition was  most likely due to the strong immune
response generated against other epitopes of rabies virus. Non-
immunized mice, which only received the virus, also produced a
similar immune response (data not shown).
In order to identify speciﬁc MAbs against the rabies glycopro-
tein, IIF assays were carried out on S2MtRVGP-Hy cells, a Drosophila
melanogaster Schneider 2 cell line expressing whole rabies virus
glycoprotein. Only MAb  8D11, which also was able to neutralize
the virus, showed a positive result in this test, conﬁrming its speci-
ﬁcity against the viral glycoprotein (Fig. 2). Surprisingly, MAb  7B7,
which was able to react against the rGERA179–281 protein, did not
bind to the glycoprotein expressed by S2MtRVGP-Hy cells. No reac-
tion was  observed when anti-IMNV MAb  was  used as the negative
control (data not shown).
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Table  1
Immunoreactivity of monoclonal antibodies against Brazilian rabies virus isolates on indirect immunoﬂuorescence assay.
Sample numbers Host LIA 02 6H8 7B7 3E6 8D11 9C7 8B6 Antigenic variant
CVS ++ ++ − ++ − ++ ++ Laboratory strain
1023 Bovine ++ ++ −  ++ + ++ − 3*
1024 Bovine ++ ++ − ++ ++ ++ − 3*
1026  Bovine ++ ++ − ++ + ++ − 3*
1027 Bovine ++ ++ − ++ ++ ++ − 3*
1032  Bovine ++ ++ − ++ ++ ++ − 3*
2429  Bovine ++ ++ − ++ ++ ++ − 3
6292  Bovine ++ ++ ++ ++ − ++ − 3
6462 Bovine ++ ++ − ++ − ++ − 3
6879  Bovine ++ ++ + ++ ++ ++ + 3
7062 Bovine ++ ++ + ++ − ++ − 3
7063  Bovine ++ ++ + ++ − ++ − 3
1028  Equine ++ ++ − ++ − ++ − 3*
6746  Equine ++ ++ − ++ − ++ − 3
7488 Human ++ ++ − − − + ++ 2
3176 Bat ++ ++ − ++ − ++ − 4
4607  Bat ++ ++ − ++ + ++ + 3
4616 Bat ++ ++ − ++ − ++ ++ 4
4697  Bat ++ ++ − ++ − ++ ++ NC
5610 Bat ++ ++ ++ ++ ++ ++ ++ 3
5787  Bat ++ ++ − ++ − ++ + 4
5861  Bat ++ ++ + ++ + ++ ++ 3
6207  Bat ++ ++ − ++ + ++ − 3
6375  Bat ++ ++ − ++ − ++ + 4
6429 Bat ++ ++ − + + − − 4
6945  Bat ++ ++ − ++ − ++ ++ NC
7279 Bat ++ ++ − ++ − ++ + 3
7952  Bat − ++ − − − + − NC
1017  Fox ++ ++ − ++ − ++ ++ 2
1043 Fox ++ ++ − ++ − ++ ++ 2
5634  Fox ++ ++ − ++ − ++ ++ 2
5636 Fox ++ ++ − + − + ++ 2
1016  Dog ++ ++ − ++ − ++ ++ 2
4194 Dog ++ ++ − ++ − ++ ++ NC
5635  Dog ++ ++ − ++ − ++ ++ 2
6634  Dog ++ ++ − ++ − ++ − 3*
C itive;
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−VS: challenge virus standard, used as positive control; −: negative; +: weakly pos
Abs  provided by CDC; 3* isolates characterized as variant 3, except for an antibod
.2. Reactivity of MAbs against wild rabies virus isolates
Aiming to investigate the possibility of using the MAbs for
iagnostic and epidemiological purposes, seven MAbs were tested
gainst 35 Brazilian rabies virus isolates from different hosts
bovines, equines, humans, bats, dogs, and foxes) on IIF assay. Based
n the observation of ﬂuorescent foci, three different reactivity pat-
erns were observed: negative, weakly positive or positive reaction.
s shown in Table 1, MAb  6H8 recognized all the virus isolates
ested. LIA 02, 3E6, and 9C7 failed to recognize only one or two of
he virus isolates. MAb  8B6 reacted with about half of the isolates,
hile 7B7 and 8D11 recognized only six and twelve isolates, respec-
ively. Comparisons between the reactivity of the CDC MAbs panel
nd those MAbs described in this study are continuing, however,
able 2
onoclonal antibody (MAb) designation, protocol of fusion through which MAbs were obt
MAbs Protocol of fusion Isotype 
LIA02 1 IgG2b 
6H8 2  IgG2a  
7B7  2 IgM 
2A5  3 IgG3 
2D2  3 IgG3 
1H2  4 IgG3 
3E6 5 IgG3
8D11 5  IgG2a  
9C7  5 IgM 
8B6 5  IgG2a  
: negative; +: positive. ++: positive; NC: variant not compatible with the proﬁles deﬁned by the panel of
e panel.
previous experiments showed 8B6 recognized the seven isolates
characterized as variant 2 and did not react against most of the
isolates from variant 3 (Table 1).
3.3. Reactivity of MAbs against inactivated rabies virus present in
commercial vaccines
The reactivity of MAbs against rabies virus vaccine strains was
evaluated to determine if MAbs can be used for the standardization
of an enzyme-immunoassay to determine rabies vaccine strength.
One reference, two human, and fourteen veterinary vaccines were
used in an immunodot-blot assay, where LIA 02, 6H8, and 9C7
reacted against all vaccine strains tested. The other MAbs, except
for 8D11, recognized almost 90% of the vaccine strains, and 8D11
ained, isotype, neutralization activity, and reactivity against protein rGERA179–281.
Virus-neutralizing activity Reaction against rGERA179–281
− −
− −
− +
− −
− −
− −
−  −
+ −
− −
− −
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Fig. 1. Immunoreactivity of monoclonal antibodies against rabies virus PV strain determined by indirect immunoﬂuorescence in rabies-infected BHK-21 cells. Cells were ﬁxed
w th MA
( J) 8B6
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iith  4% paraformaldehyde, permeabilized with 0.25% Triton X-100, and stained wi
A)  LIA 02; (B) 6H8; (C) 7B7; (D) 2A5; (E) 2D2; (F) 1H2; (G) 3E6; (H) 8D11; (I) 9C7; (
hich  infects marine invertebrates); (L) positive control: sera of rabies virus-immu
eacted against 70% of them (Table 3). The anti-IMNV MAb  used as
he negative control did not react with any of the vaccine strains
data not shown).
. Discussion
The present report describes the generation of ten MAbs
gainst rabies viruses. Mice were immunized with: (1) a rabies
accine VeroRabTM, which contains -propiolactone-inactivated
abies virus, (2) three different suspensions of central nervous
ystem tissue from mice infected with UV light-inactivated wild
abies viruses, (3) a recombinant fragment of rabies glycoprotein,
GERA179–281, and rabies virus PV strain. Six hybridomas were
btained from the fusion of mouse myeloma cells with splenocytes
ig. 2. Reactivity of monoclonal antibodies against the rabies virus glycoprotein expresse
nduced  to express the rabies virus glycoprotein using 700 M of CuSO4, ﬁxed with aceton
mmunoglobulin. (A) LIA 02; (B) 8D11. The other MAbs were negative and are not shownbs against rabies virus, followed by FITC-conjugated anti-mouse immunoglobulin.
; (K) negative control anti-IMNV MAb  (a non-related MAb  that binds IMNV, a virus
 mice. Scale bars are 100 m.
from Balb/c mice immunized with rabies vaccines or with wild
rabies isolates. Since these hybridomas did not produce neutraliz-
ing antibodies, the immunization of mice with the rGERA179–281
protein was  performed in order to obtain the neutralizing MAbs.
rGERA179–281 is a recombinant protein comprising linear epi-
topes (residues 179–281) from the glycoprotein of the ERA rabies
virus strain expressed in Escherichia coli. By competition assay,
this protein led to a measurable reduction in the ability of human
rabies immunoglobulin to neutralize rabies virus (Bassi et al., 2008).
The production of rabies-neutralizing antibodies in animals immu-
nized with a fragment of the rabies glycoprotein expressed in
E. coli has been described previously (Motoi et al., 2005). In the
present study, immunization of mice with the recombinant protein
rGERA179–281 also induced neutralizing antibodies to rabies virus,
d by S2MtRVGP-Hy cells, determined by indirect immunoﬂuorescence. Cells were
e (80%), and stained with anti-rabies MAb  followed by FITC-conjugated anti-mouse
 in this ﬁgure. Scale bars are 100 m.
C. Zanluca et al. / Journal of Virological Methods 175 (2011) 66– 73 71
Table  3
Immunodot-blot assay of the immunoreactivity of monoclonal antibodies against ﬁxed rabies virus strains employed in vaccine production.
Vaccine identiﬁcation Rabies strain LIA 02 6H8 7B7 2A5 2D2 1H2 3E6 8D11 9C7 8B6
Reference vaccine CVS + + + + + + + − + +
H1 PM + + + + + + + + + +
H2 Flury LEP + + − + + + + + + +
V1  PV + + + + + + + + + +
V2  PV + + + + + + + + + +
V3  CVS + + − + + + + − + +
V4  Paris Pasteur + + + + + + + + + +
V5 WI−38  + + + + + + + + + +
V6 WI−38  + + + − − − − − + −
V7 PV  + + + + + + + + + +
V8  PV + + + + + + + − + +
V9  ERA + + + + − − + + + +
V10  PM + + + + + + + − + +
V11 CVS + + + + + + + + + +
V12  PV-12 + + + + + + + + + +
V13 PV-12 + + + + + + + + + +
− .
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: negative; +: positive; H1 and H2: human vaccines; V1–V14: veterinary vaccines
lthough in low titers (data not shown). Four MAbs were obtained
rom this fusion, including a rabies neutralizing MAb. However, sur-
risingly, a strong immune response also was induced by the boost
n mice not immunized previously with the rGERA179–281 pro-
ein (data not shown), and none of these four MAbs recognized
he recombinant protein. Together, these data suggest the boost
ith rabies virus PV strain (not the rGERA179–281 protein) was
esponsible for the production of MAbs 3E6, 9C7, 8D11, and 8B6.
In the present work, a relatively limited amount of useful
Abs was obtained for each immunization protocol. In fact, on
verage <1–5% of the growth-positive wells during a typical
usion will contain hybridomas that secrete the desired antibody
Yokoyama et al., 2006). However, the number of hybridomas
chieved in the fusion process can vary widely according to dif-
erent authors. For example, Benmansour et al. (1991) immunized
ice with -propiolactone-inactivated CVS and obtained several
undred MAbs against rabies. On the other hand, Jiang et al.
2010) immunized mice with a sucrose-gradient-puriﬁed and -
ropiolactone-inactivated rabies virus L16 strain and obtained 25
Abs, while Akacem et al. (1992) obtained only seven MAbs when
ice were immunized with a wild rabies virus. Several possi-
le explanations for the limited amount of MAbs obtained in the
resent report may  exist. One explanation could be the great insta-
ility of hybrid cells in the ﬁrst days after fusion due to the loss
f some chromosomes (Köhler and Milstein, 1975), which may
esult in non-antibody-producing hybridomas or in hybrid cells
hat are unsuitable for survival in HAT culture medium (Taggart
nd Samloff, 1983; Zola, 1987). Non-secreting hybridomas and
lones with an unstable assortment of chromosomes may  also
e present in the original well and may  outgrow and replace the
esired antibody-producing hybridomas (Sheehan, 2007). The use
f non-puriﬁed antigens in the immunization process, such as
abies vaccine or infected mouse brain suspension, may  result in
he production of MAbs against many other antigens (Yokoyama
t al., 2006). In the present work, many hybridomas with a positive
esult in the screening test secreted antibodies that cross-reacted
ith non-infected BHK-21 cells (data not shown), possibly due to
he presence of the non-puriﬁed antigens.
Seven MAbs described in this study showed different reactivity
gainst wild rabies virus isolates on immunoﬂuorescence assays,
ith MAbs recognizing varying numbers of isolates from six to all
f the 35 isolates tested. Among them, LIA 02, 6H8, 3E6, and 9C7
ecognized all or almost all of the isolates tested, suggesting that
hese MAbs may  be important in the future as diagnostic tools. For
xample, these MAbs may  be labeled with FITC and used for routine
iagnosis.+ + + + + + +
Currently, the most widely used test for the detection of
rabies antigens is the direct ﬂuorescent antibody test, which uses
FITC-conjugated anti-rabies antibodies (Woldehiwet, 2005). These
conjugated antibodies often are obtained from the sera of immu-
nized animals, which may  contain non-rabies antibodies (Dean
et al., 1996). The use of MAbs may  increase the speciﬁcity of the
conjugate, reduce the variation between different batches, and also
help to distinguish rabies virus from other types of Lyssavirus.
The MAbs generated in the present study also may  be useful
for the development of rapid immunoassays such as ELISA, latex
agglutination test, and immunochromatographic strip test to detect
rabies virus in infected animals (Kang et al., 2007; Kasempimolporn
et al., 2000; Nishizono et al., 2008) or to quantify anti-rabies serum
neutralizing antibodies in immunized animals (Shiota et al., 2009;
Wang et al., 2010; Zhang et al., 2009).
The use of MAb  panels also allowed the identiﬁcation of com-
mon  rabies virus variants and the enhancement of epidemiological
studies, serving as a useful tool for geographical distribution anal-
ysis of the virus and animals hosts around the world, including the
USA (Crawford-Miksza et al., 1999), Europe, and Russia (Bourhy
et al., 1992; Metlin et al., 2004). Studies with isolates from Latin
America are developed mainly using a panel of eight MAbs pro-
vided by CDC (Castilho et al., 2010; Diaz et al., 1994). By identifying
the rabies virus antigenic pattern, these studies permit the iden-
tiﬁcation of the most likely rabies transmitter or rabies reservoir.
However, as demonstrated by Favoretto et al. (2002),  antigenic vari-
ants have been identiﬁed in Brazil which are not compatible with
the current panel of MAbs used to characterize isolates in the Amer-
icas. In turn, this identiﬁcation of new antigenic proﬁles restricts
the use of the current MAb  panel to identify potentially emergent
rabies reservoirs, suggesting new MAbs are needed to complement
this panel. Comparisons between the reactivity of the seven MAbs
described here against wild rabies isolates and the panel of MAbs
provided by CDC showed that 8B6 is the most promising MAb for
this purpose. In this present report, 8B6 reacted against all seven
isolates characterized as variant 2, and did not react against most
of the isolates from variant 3, suggesting 8B6 could be employed
in epidemiological studies. However, further studies with a greater
number of isolates still are needed in order to verify if the reac-
tivity of 8B6 against isolates from different variants is compatible
with the genetic characterization of the isolates, including variants
which are incompatible with the proﬁles deﬁned in the panel of
MAbs provided by CDC.
Vaccine strength is currently determined by the NIH test, which
uses a large number of live animals and presents several prob-
lems in terms of reproducibility (Barth et al., 1988; Wilbur and
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ubert, 1996). A new assay to replace the NIH test may  not only
vercome these problems, but, as an advantage, would also avoid
andling live rabies virus. MAbs, especially those speciﬁc against
he rabies glycoprotein, have been employed in the development
f immunoassays, such as ELISA, to determine vaccine strength and
or quality control during vaccine production (Fournier-Caruana
t al., 2003; Nagarajan et al., 2006). These methods are based
n determining the antigen content of vaccine preparations, i.e.,
easuring the content of glycoprotein and/or RNP. In the present
tudy, the reactivity of the MAbs against ﬁxed rabies virus strains
resent in commercial vaccines was evaluated. One reference, two
uman, and fourteen veterinary vaccines, comprising eight differ-
nt rabies strains, were tested. Three MAbs reacted against rabies
irus strains present in all the vaccines tested and the remaining
Abs recognized twelve or more vaccine strains, as demonstrated
y immunodot-blot assay. These results warrant further studies
n the use of MAbs for the standardization of an immunoassay to
etermine the strength of rabies vaccines. The results presented
n this paper suggest the most promising MAbs to be employed in
urther studies are LIA 02, 6H8, 3E6, and 9C7, which recognized
ore than 94% of wild rabies isolates, and 8D11, which showed
eutralizing activity against rabies virus.
The anti-glycoprotein speciﬁcity of MAb  8D11, which presents
n IIF staining pattern located predominantly on the cell mem-
rane, was conﬁrmed by IIF on S2MtRVGP-Hy cells. This MAb  also
howed rabies virus-neutralizing activity in vitro, preventing the
nfection of BHK-21 cells by rabies virus. These results support the
nvestigation of the protective activity of MAb  8D11 in vivo. The
n vivo protective activity of some MAb  cocktails has been investi-
ated by other authors as a possible post-exposure treatment for
abies (Bakker et al., 2008; Müller et al., 2009).
In conclusion, the present report describes the generation of ten
Abs against rabies virus. The reactivity pattern of MAb 8B6 with
ild rabies virus strains, when compared with the panel of MAbs
rovided by CDC, highlights the potential of 8B6 to be employed in
pidemiological studies. In addition, MAb  8D11 was able to neutral-
ze the virus in vitro, and MAbs 6H8, LIA 02, 3E6, and 9C7 recognized
 greater number of wild rabies virus isolates and ﬁxed rabies
trains present in the commercial vaccines tested. Therefore, these
Abs may  be considered the most promising to be employed in
urther diagnosis and immunoassay studies.
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